TMCnet News
European Minimally-Invasive Replacement of Mitral Valve for Mitral Regurgitation Market 2017 - Research and MarketsResearch and Markets has announced the addition of the "Minimally-Invasive Replacement of Mitral Valve for Mitral Regurgitation" report to their offering. This report presents summary of the reimbursement situation for a minimally-invasive (transapical via mini-thoracotomy) replacement of mitral valve for mitral regurgitation. Report includes essential information about reimbursement and national funding of the minimally-invasive replacement of mitral valve for mitral regurgitation, including: - Brief overview of reimbursement system for medical devices - Procedure coding for technology - Diagnosis coding - Payment mechanism for technology - Reimbursement tariffs for technology - Restrictions in indications or scenarios fo use of technology - Policy considerations by payers and policy-makers about technology Key Topics Covered: 1. Introduction and summary 2. Executive summary table 3. Contents 4. Methodology 5. Reimbursement analysis in Austria 6. Reimbursement analysis in Belgium 7. Reimbursement analysis in Denmark 8. Reimbursement analysis in England 9. Reimbursement analysis in France 10. Reimbursement analysis in Germany 11. Reimbursement analysis in Italy 12. Reimbursement analysis in the Netherlands 13. Reimbursement analysis in Norway 14. Reimbursement analysis in Sweden 15. Reimbursement analysis in Switzerland Companies Mentioned - Abbott Vascular (Tendyne valve) - Cephea - Edwards Lifesciences (SAPIEN XT valve, CardiAQ-Edwards Transcatheter Mitral Valve, Fortis transcatheter mitral valve) - Micro Interventional Devices (Permavalve) - NaviGate Cardiac Structures (NAVI System) - Neovasc (Tiara device) For more information about this report visit http://www.researchandmarkets.com/research/rvt56x/minimallyinvasive
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522006025/en/ |
